BioSpace News Archive

Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced a joint marketing agreement with Glytec, the market leader and pioneer of insulin titration solutions for use across the full continuum of care.

Soliton, Inc. (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that its 510(k) application for premarket clearance filed with the U.S. Food and Drug Administration (“FDA”) for its first generation Rapid Acoustic Pulse (“RAP”) tattoo removal device has cleared the agency’s acceptance review.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the Ambulatory Blood Pressure Monitoring clinical study (NCT03868059) (“ABPM Study”) designed to study TLANDO’s effects on blood pressure.

Mirum Pharmaceuticals announced today that data from three of its programs will be presented at the International Liver Congress™ 2019, occurring in Vienna, Austria, from April 10-14, 2019, at the Reed Messe Wien Exhibition & Congress Center.

For the second year, Fresenius Medical Care North America (FMCNA), the largest provider of dialysis products and services, will serve as National Presenting Sponsor for the National Kidney Foundation’s 2019 Kidney Walks

Further validating its ApoGraft™ technology, Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced positive mid-study data from the Company’s Phase I/II study of its ApoGraft™ technology

According to new data released today, the Express Scripts SafeGuardRx® offering – the company’s first-to-market value-based programs for employers and health plans – improved patient engagement and increased medication adherence while reducing costs for some of the nation’s costliest therapies.

Imara Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, today announced it has hired Willem H. Scheele, M.D., as Chief Medical Officer.

Axcella Health announced a late-breaker poster presentation for their novel endogenous metabolic modulator composition, AXA1665 in subjects with mild and moderate hepatic insufficiency.

Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2019 American Association for Cancer Research (“AACR”) Annual Meeting taking place March 29 - April 3, 2018 in Atlanta, Georgia.